麗珠醫藥(01513.HK)收購麗珠生物股權並增資
麗珠醫藥(01513.HK)公布,為實現重組框架協議,公司與健康元分別與麗珠香港簽訂了股權轉讓協議,雙方同意分別以2,431.6萬元人民幣(下同)對應認繳出資額1.275億元)及2,336.3萬元福對應認繳出資額1.225億元)的價格,向麗珠香港收購麗珠生物51%及49%的股權。
另外,公司、健康元、麗生聚源與麗珠生物簽訂了增資協議,麗珠生物的註冊資本由2.5億元增加至6.67億元,其中公司認繳1.785億元的出資額。增資完成後,麗珠生物將分別由公司、健康元及麗生聚源持有45.90%、44.10%及10%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.